MA30563B1 - Sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide - Google Patents

Sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide

Info

Publication number
MA30563B1
MA30563B1 MA31469A MA31469A MA30563B1 MA 30563 B1 MA30563 B1 MA 30563B1 MA 31469 A MA31469 A MA 31469A MA 31469 A MA31469 A MA 31469A MA 30563 B1 MA30563 B1 MA 30563B1
Authority
MA
Morocco
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
MA31469A
Other languages
English (en)
Inventor
Murat Acemoglu
Joginder S Bajwa
Piotr Karpinski
Dimitris Papoutsakis
Joel Slade
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30563(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30563B1 publication Critical patent/MA30563B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la préparation et la caractérisation de sels de N- hydroxy-3-[4-[[[2-(2-méthyl-1H-indol-3-yl)éthyl]amino]méthyl]phényl]-2E-2- propénamide.
MA31469A 2006-06-12 2008-12-12 Sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide MA30563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
MA30563B1 true MA30563B1 (fr) 2009-07-01

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31469A MA30563B1 (fr) 2006-06-12 2008-12-12 Sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide

Country Status (38)

Country Link
US (3) US20090197936A1 (fr)
EP (1) EP2032531B1 (fr)
JP (2) JP2009540005A (fr)
KR (2) KR20090026281A (fr)
AR (1) AR061298A1 (fr)
AU (1) AU2007257962B2 (fr)
BR (1) BRPI0712771A2 (fr)
CA (1) CA2654439C (fr)
CL (1) CL2007001692A1 (fr)
CR (1) CR10439A (fr)
DK (1) DK2032531T3 (fr)
EA (1) EA015212B1 (fr)
EC (1) ECSP088979A (fr)
ES (1) ES2570934T3 (fr)
GE (1) GEP20105125B (fr)
GT (1) GT200800279A (fr)
HK (1) HK1126496A1 (fr)
HN (1) HN2008001859A (fr)
HR (1) HRP20160291T1 (fr)
HU (1) HUE027126T2 (fr)
IL (1) IL195087A (fr)
JO (1) JO3138B1 (fr)
MA (1) MA30563B1 (fr)
ME (1) ME00531B (fr)
MX (1) MX2008015901A (fr)
MY (1) MY147345A (fr)
NO (1) NO341871B1 (fr)
NZ (1) NZ572547A (fr)
PE (1) PE20080937A1 (fr)
PL (1) PL2032531T3 (fr)
RS (1) RS54640B1 (fr)
SI (1) SI2032531T1 (fr)
SM (1) SMP200900002B (fr)
SV (1) SV2008003126A (fr)
TN (1) TNSN08501A1 (fr)
TW (1) TWI409254B (fr)
UY (1) UY30403A1 (fr)
WO (1) WO2007146715A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584673B (zh) 2006-06-12 2014-08-06 诺华股份有限公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的多晶型物
KR20090098920A (ko) * 2007-01-10 2009-09-17 노파르티스 아게 데아세틸라제 억제제의 제제
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (fr) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Nouveaux sels et formes polymorphes de panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
BRPI0713653A2 (pt) * 2006-06-12 2012-10-23 Novartis Ag processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
CN102584673B (zh) * 2006-06-12 2014-08-06 诺华股份有限公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的多晶型物

Also Published As

Publication number Publication date
HK1126496A1 (zh) 2009-09-04
JO3138B1 (ar) 2017-09-20
RS54640B1 (en) 2016-08-31
TWI409254B (zh) 2013-09-21
CA2654439A1 (fr) 2007-12-21
ES2570934T3 (es) 2016-05-23
ME00531B (fr) 2011-10-10
KR20090026281A (ko) 2009-03-12
JP2013256542A (ja) 2013-12-26
MX2008015901A (es) 2009-01-12
UY30403A1 (es) 2008-01-31
DK2032531T3 (en) 2016-04-11
EA200802382A1 (ru) 2009-06-30
TNSN08501A1 (en) 2010-04-14
NO20090128L (no) 2009-03-11
CL2007001692A1 (es) 2008-05-09
PE20080937A1 (es) 2008-08-29
JP2009540005A (ja) 2009-11-19
GT200800279A (es) 2010-06-16
BRPI0712771A2 (pt) 2012-09-25
JP5771257B2 (ja) 2015-08-26
PL2032531T3 (pl) 2016-07-29
US20110112308A1 (en) 2011-05-12
AR061298A1 (es) 2008-08-20
TW200815343A (en) 2008-04-01
HUE027126T2 (en) 2016-08-29
AU2007257962B2 (en) 2011-06-23
EP2032531A1 (fr) 2009-03-11
HN2008001859A (es) 2011-07-19
SMP200900002B (it) 2010-01-19
GEP20105125B (en) 2010-11-25
KR101629352B1 (ko) 2016-06-13
ECSP088979A (es) 2009-01-30
AU2007257962A1 (en) 2007-12-21
IL195087A0 (en) 2009-08-03
NZ572547A (en) 2011-06-30
WO2007146715A1 (fr) 2007-12-21
SI2032531T1 (sl) 2016-05-31
SMAP200900002A (it) 2009-01-14
US20090197936A1 (en) 2009-08-06
EA015212B1 (ru) 2011-06-30
NO341871B1 (no) 2018-02-12
EP2032531B1 (fr) 2016-02-10
CR10439A (es) 2009-01-15
MY147345A (en) 2012-11-30
CA2654439C (fr) 2014-08-05
IL195087A (en) 2012-10-31
KR20150029765A (ko) 2015-03-18
HRP20160291T1 (hr) 2016-04-22
US20100286409A1 (en) 2010-11-11
SV2008003126A (es) 2011-07-05

Similar Documents

Publication Publication Date Title
MA30563B1 (fr) Sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
IL233836A0 (en) Method for preparing n-hydroxy-3-[4-[[[2-(2-methyl-h1-indol-3-yl)ethyl]amino]methyl]phenyl]-e2-2-propanamide
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida